Cero Therapeutics Hldgs Inc.
13F holders, Q1 2025 (March 31)15holders +14
7new positions
0sold out
1famous investor
$0.73avg. 13F price*
At the end of Q1 2025, 15 institutions reported holding Cero Therapeutics Hldgs Inc. in their 13F filings, up 14 from Q4 2024. 7 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($228K), Parallel Advisors, LLC ($161K) and Avantax Planning Partners, Inc. ($54K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Cero Therapeutics Hldgs Inc.
- CUSIP
- 71902K303
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $454K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 674,029 shares bought and 77,248 shares sold, net +596,781 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Armistice Capital, LLC | 0.01% | New | 312,000 | $228K |
| Parallel Advisors, LLC | 0.00% | New | 220,000 | $161K |
| Avantax Planning Partners, Inc. | 0.00% | Add +187.5% | 74,321 | $54K |
| UBS Group AG | 0.00% | New | 42,687 | $31K |
| ARCH Venture Management, LLC | 0.01% | Reduce -76.5% | 22,102 | $16K |
| Geode Capital Management, LLC | 0.00% | New | 16,917 | $12K |
| Citadel Advisors | 0.00% | New | 16,218 | $12K |
| Susquehanna International Group, LLP | 0.00% | New | 13,343 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +581.1% | 5,018 | $4K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -98.0% | 110 | $80 |
| Barclays PLC | 0.00% | New | 102 | $74 |
| Bank of America Corp. | 0.00% | Add +162.8% | 18 | $13 |
| Osaic Holdings, Inc. | 0.00% | No change | 4 | $2 |
| JPMorgan Chase & Co. | 0.00% | Reduce -28.6% | 1 | $1 |
| FNY Investment Advisers, LLC | 0.00% | Reduce -0.2% | 262 | $0 |
"% of holder's portfolio" is CERO THERAPEUTICS HLDGS INC's weight in each manager's 13F, not the share of Cero Therapeutics Hldgs Inc. the manager owns.